Magenta Therapeutics (NASDAQ: MGTA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We are updating our MGTA company model after assuming research coverage of the company and also incorporating updates related to the company’s revised operating plan. We agree with their efforts to emphasize the MGTA-117 targeted conditioning program, given its potentially transformative nature. Management will also continue IND-enabling activities for their CD45-ADC and MGTA-145 stem cell mobilization efforts in sickle cell disease but will de-prioritize other investments to navigate the challenging capital market environment and extend their expected cash runway into 2Q 2024 (from 4Q 2023). Our model updates lower our DCF-derived price target to $8 (from $17), but we maintain our Buy rating given the potential upside from the current valuation.”

To request access to the full report, visit https://ibn.fm/f1ahI

About Magenta Therapeutics Inc.

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise to revolutionize immune and blood reset to allow more patients to take advantage of the curative potential of stem cell transplant as well as potentially improve eligibility for future gene therapies. Magenta is based in Cambridge, Mass. For more information, visit the company’s website at www.Magentatx.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.